Management of cystic fibrosis (CF)-related diabetes (CFRD) is evolving as the CF population experiences increasing rates of overweight and obesity, particularly with the widespread use of CF transmembrane conductance regulator (CFTR) modulators. This article describes practical insights from implementing a pilot program that evaluated injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in adults with CFRD. Our program followed 11 participants over 12 months, revealing important considerations for patient selection, monitoring protocols, and managing adverse effects in this unique population. Although most participants tolerated semaglutide well with clinically meaningful improvements observed in glycemic management, careful screening and close follow-up proved essential. These findings offer practical guidance for diabetes educators and clinicians considering GLP-1 RA therapy as an adjunct to insulin in carefully selected patients with CFRD.
Keywords: GLP-1 receptor agonist, agoniste des récepteurs du GLP-1, contrôle glycémique, cystic fibrosis, diabetes, diabète, fibrose kystique, glycemic management, obesity, obésité
Canadian journal of diabetes
Journal Article
English
42331284
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.